Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted psychotherapy for PTSD
ACTRN12624000041550Phase 4Recruiting
- Sponsor
- Dr and A/ Professor Ranil Gunewardene
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Dr and A/ Professor Ranil Gunewardene. Primary endpoint: Change in clinician-rated PTSD symptoms from baseline. Started May 2024; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12624000041550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000041550.